Genes vs environment in inflammatory bowel disease: an update

被引:10
作者
Dipasquale, Valeria [1 ]
Romano, Claudio [1 ]
机构
[1] Univ Messina, Pediat Gastroenterol & Cyst Fibrosis Unit, Dept Human Pathol Adulthood & Childhood G Barresi, Via Consolare Valeria 1, I-98124 Messina, Italy
关键词
Environment; gene; inflammatory bowel disease; risk factor; very early onset inflammatory bowel disease; CROHNS-DISEASE; ULCERATIVE-COLITIS; PEDIATRIC GASTROENTEROLOGY; WIDE ASSOCIATION; RECENT INSIGHTS; ACTIVE DISEASE; POSITION PAPER; TWIN COHORT; FOLLOW-UP; RISK;
D O I
10.1080/1744666X.2022.2108407
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Inflammatory bowel diseases (IBDs) are known to be caused by a combination of genetic and environmental factors that vary in their influence on the development of the disease. Environmental exposures seem to influence IBD susceptibility, whereas genetic background is thought to modulate the impact of the environment on disease course and phenotype. Areas covered A broad review of the involvement of genes and the environment in IBD pathogenesis was performed, and information regarding the main genetic and environmental factors - categorized into lifestyle factors, drugs, diet, and microbes - was updated. Monogenic very early onset IBD (VEO-IBD) was also discussed. Expert opinion In the upcoming years, better understanding of gene-environment interactions will contribute to the possibility of a better prediction of disease course, response to therapy, and therapy-related adverse events with the final goal of personalized and more efficient patient management.
引用
收藏
页码:1005 / 1013
页数:9
相关论文
共 50 条
  • [21] Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease
    Johnson C.M.
    Dassopoulos T.
    Current Gastroenterology Reports, 2018, 20 (11)
  • [22] Abnormal gut motility in inflammatory bowel disease: an update
    G. Bassotti
    E. Antonelli
    V. Villanacci
    R. Nascimbeni
    M. P. Dore
    G. M. Pes
    G. Maconi
    Techniques in Coloproctology, 2020, 24 : 275 - 282
  • [23] UPDATE OF IMMUNOMODULATORY THERAPY FOR INFLAMMATORY BOWEL-DISEASE
    BERNSTEIN, CN
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 1994, 8 (07): : 413 - 416
  • [24] Update in the management of extraintestinal manifestations of inflammatory bowel disease
    Patil S.A.
    Cross R.K.
    Current Gastroenterology Reports, 2013, 15 (3)
  • [25] Abnormal gut motility in inflammatory bowel disease: an update
    Bassotti, G.
    Antonelli, E.
    Villanacci, V.
    Nascimbeni, R.
    Dore, M. P.
    Pes, G. M.
    Maconi, G.
    TECHNIQUES IN COLOPROCTOLOGY, 2020, 24 (04) : 275 - 282
  • [26] Nutritional treatment in inflammatory bowel disease. An update
    Guagnozzi, Danila
    Gonzalez-Castillo, Sonia
    Olveira, Antonio
    Lucendo, Alfredo J.
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2012, 104 (09) : 479 - 488
  • [27] Update on Janus Kinase Antagonists in Inflammatory Bowel Disease
    Boland, Brigid S.
    Sandborn, William J.
    Chang, John T.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2014, 43 (03) : 603 - +
  • [28] Update: chronic inflammatory Bowel Disease
    Atreya, Raja
    Neumann, Helmut
    Neurath, Markus Friedrich
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (23) : 1762 - U100
  • [29] Phenome of coeliac disease vs. inflammatory bowel disease
    Kleinjans, Moritz
    Schneider, Carolin, V
    Bruns, Tony
    Strnad, Pavel
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [30] An update on the safety of long-term vedolizumab use in inflammatory bowel disease
    Honap, Sailish
    Netter, Patrick
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (09) : 767 - 776